Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI
Por um escritor misterioso
Descrição
In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.
Therapeutic implications of menin inhibition in acute leukemias
Treatment National Cancer Institute
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant
Revumenib: a new therapy for AML patients
ASH: Novel menin inhibitors show promise for patients with
NRG1 Fusions Hold Promise as Pan-tumor Target
Medical Advances in Leukemia Research
I-131 apamistamab induces response among adults with advanced
Revumenib trial meets complete remission endpoint for acute
Clinical Trial Results National Cancer Institute
National Cancer Institute (NCI) on LinkedIn: #ncifuture
Revumenib Shows Promise in Acute Leukemia - CancerConnect
Revumenib Shows Promise in Acute Leukemia - CancerConnect
de
por adulto (o preço varia de acordo com o tamanho do grupo)
